Molecular analysis in Spanish patients with muscle carnitine palmitoyltransferase deficiency

Muscle Nerve. 1999 Jul;22(7):941-3. doi: 10.1002/(sici)1097-4598(199907)22:7<941::aid-mus20>3.0.co;2-z.

Abstract

The most common mutation in muscle carnitine palmitoyltransferase II (CPT II) deficiency is a missense mutation that replaces a leucine for a serine residue at amino acid position 113 of the CPT II protein (S113L). We performed molecular analysis in a group of 14 Spanish patients with CPT II deficiency from ten unrelated families. The S113L mutation was observed in 8 of the 14 patients studied. Seven patients were homozygous for the mutation, 1 patient was heterozygous, and 6 patients did not carry the mutation on either allele. Seven healthy relatives belonging to three different families carried the mutation on one allele. One patient carried the missense mutation that replaces a tyrosine for a serine at amino acid position 628 on one allele. Our data indicate that the S113L is also the most common mutation in Spanish patients with CPT II deficiency in muscle, and that further pathogenic mutations remain to be identified.

Publication types

  • Clinical Trial
  • Research Support, Non-U.S. Gov't

MeSH terms

  • Carnitine O-Palmitoyltransferase / deficiency*
  • Carnitine O-Palmitoyltransferase / genetics
  • Female
  • Heterozygote
  • Homozygote
  • Humans
  • Male
  • Muscles / enzymology*
  • Mutation, Missense
  • Spain

Substances

  • Carnitine O-Palmitoyltransferase